StoneX Group’s PDS Biotechnology PDSB Stock Holding History

StoneX Group’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,000	Closed	-$12.3K	–	1170
2025 Q4	$12.3K	Buy	+16,000	New	+$14.4K	﹤0.01%	993

Other funds holding PDSB

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

StoneX Group's PDSB Position: Q1 2026 in Review

StoneX Group sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 16,000 shares — an estimated $12.3K sold.

StoneX Group first reported a position in PDSB in Q4 2025 and held it in 1 quarter. The position peaked at $12.3K in Q4 2025. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

StoneX Group reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 16,000 PDS Biotechnology shares in Q1 2026, an estimated $12.3K.
StoneX Group first reported a position in PDS Biotechnology in Q4 2025 and held it in 1 quarter.
StoneX Group's PDS Biotechnology position peaked at $12.3K in Q4 2025.
41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.